###begin article-title 0
Valproate, a Mood Stabilizer, Induces WFS1 Expression and Modulates Its Interaction with ER Stress Protein GRP94
###end article-title 0
###begin p 1
Conceived and designed the experiments: CK SI CMO TK FU. Performed the experiments: CK SI CMO SGF. Analyzed the data: CK SI CMO FU. Wrote the paper: CK SI CMO SGF TK FU.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Valproate is a standard treatment for bipolar disorder and a first-line mood stabilizer. The molecular mechanisms underlying its actions in bipolar disorder are unclear. It has been suggested that the action of valproate is linked to changes in gene expression and induction of endoplasmic reticulum (ER) stress-response proteins.
###end p 3
###begin title 4
Principal Findings
###end title 4
###begin p 5
Here we show that valproate modulates the ER stress response through the regulation of WFS1, an important component for mitigating ER stress. Therapeutic concentrations of valproate induce expression of WFS1 mRNA and activate the WFS1 promoter. In addition, WFS1 forms a complex with GRP94, an ER stress-response protein, in which valproate dose-dependently enhances its dissociation from GRP94.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
These results suggest that the therapeutic effects of valproate in bipolar disorder may be mediated by WFS1 expression and its dissociation from GRP94.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 147 150 147 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Goodwin1">[1]</xref>
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kato1">[2]</xref>
###xml 418 421 418 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Rosenberg1">[3]</xref>
###xml 423 426 423 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Johannessen1">[4]</xref>
###xml 428 431 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Johannessen2">[5]</xref>
###xml 840 843 836 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Rosenberg1">[3]</xref>
###xml 845 848 841 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Johannessen1">[4]</xref>
###xml 850 853 846 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Johannessen2">[5]</xref>
Bipolar disorder is a severe mental disorder characterized by recurrent episodes of mania and depression, affecting about 0.5-1% of the population [1]. Although the pathogenesis of bipolar disorder is unclear, it is known that mood stabilizers, such as valproate, can prevent its recurrence [2]. Valproate, a simple branched-chain fatty acid, has been used in the treatment of bipolar disorder, epilepsy, and migraine [3], [4], [5]. Valproate increases the level of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), with acute administration causing a 15%-45% increase in GABA in the brains of rodents. Because inhibition of GABAergic signaling can cause seizures and potentiation of GABA signaling can prevent seizures, this effect of valproate on GABA levels has been proposed as a mechanism for its anticonvulsant activity [3], [4], [5].
###end p 9
###begin p 10
###xml 409 412 409 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Chen1">[6]</xref>
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Chen2">[7]</xref>
###xml 671 674 671 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Phiel1">[8]</xref>
The molecular mechanisms of valproate in bipolar disorder are unclear. One hypothesis is that the therapeutic effect of valproate in bipolar disorder may be mediated by changes in expression of neuroprotective genes. Valproate increases the DNA binding of activator protein 1 (AP-1), a transcription factor which is a heterodimeric protein composed of proteins belonging to the c-Fos, c-Jun, and ATF families [6], [7]. This may lead to enhanced expression of AP-1 target genes that have important functions in neurons. In addition, valproate has been characterized as a histone deacetylases (HDAC) inhibitor and can regulate gene expression through epigenetic mechanisms [8]. These findings suggest an attractive possibility that valproate increases expression of multiple genes that have protective effects against bipolar disorder.
###end p 10
###begin p 11
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Ron1">[9]</xref>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Rutkowski1">[10]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kozutsumi1">[11]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Yoshida1">[12]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Christianson1">[13]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi1">[14]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Fonseca1">[15]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Inoue1">[16]</xref>
###xml 829 833 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Strom1">[17]</xref>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Hardy1">[18]</xref>
###xml 954 958 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Swift1">[19]</xref>
###xml 1109 1113 1109 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Swift2">[20]</xref>
###xml 1207 1211 1207 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Swift3">[21]</xref>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
The unfolded protein response (UPR) is a gene expression program that modulates endoplasmic reticulum (ER) stress, a specific type of cell stress caused by the accumulation of misfolded proteins in the ER [9], [10]. GRP94 is a component of the UPR and has a function in protein folding and degradation [11], [12], [13]. Genetic variations in the GRP94 gene are associated with bipolar disorder in the Japanese population [14]. High throughput proteomics analysis revealed that GRP94 interacts with WFS1 protein (Fonseca and Urano, unpublished data). WFS1 is also a component of the UPR and regulates cellular ER stress levels [15]. WFS1 was initially identified as a causative gene for Wolfram syndrome, a rare autosomal recessive disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy and deafness [16], [17], [18]. About 60% of patients with Wolfram syndrome have some mental disturbance such as severe depression and psychosis [19]. Importantly, even the heterozygotes who do not have Wolfram syndrome are 26-fold more likely than non-carriers to have a psychiatric hospitalization [20], and the relative risk of psychiatric hospitalization for depression was estimated to be 7.1 [21]. These findings suggest that the modulation of ER stress by WFS1 and GRP94 may be involved in bipolar disorder.
###end p 11
###begin p 12
Here we show that valproate regulates WFS1 and GRP94 in neurons. Valproate activates the WFS1 promoter and induces WFS1 mRNA expression in neuronal cells. Under normal conditions, WFS1 forms a complex with GRP94 and valproate enhances its dissociation from GRP94. Our data raise the possibility that the therapeutic effects of valproate in bipolar disorder may be mediated by the modulation of ER stress through the regulation of WFS1 and GRP94.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
Valproate increases the expression of WFS1 without inducing other ER stress markers
###end title 14
###begin p 15
###xml 297 306 297 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g001">Figure 1A</xref>
###xml 426 435 426 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g001">Figure 1A</xref>
To investigate the possible involvement of valproate in WFS1 function in neurons, we first determined expression levels of WFS1 in neuronal cell lines treated with a therapeutic concentration of valproate. Valproate increased WFS1 protein expression levels in Neuro-2a cells with a peak at 24 hr (Figure 1A, upper panel). Another mood stabilizer, lithium, did not increase WFS1 expression levels significantly in these cells (Figure 1A, lower panel).
###end p 15
###begin title 16
Valproate increases the expression of WFS1 without inducing other ER stress markers.
###end title 16
###begin p 17
(A) Neuro-2a cells were treated with valproate (VPA, 100ug/ml) or lithium (Li, 1mM) for 4 hr, 24 hr, and 48 hr. Expression levels of Wfs1, phospho-eIF2alpha (P-eIF2alpha) and Actin were measured by immunoblot. The relative amounts of the proteins, Wfs1 and P-eIF2alpha, which are adjusted by the amount of actin, are shown in the right panels. (B) Expression levels of Wfs1, GRP94, GRP78, total Xbp-1, spliced Xbp-1, and Aatf were measured by quantitative real-time PCR (n = 3; values are mean+/-SD).
###end p 17
###begin p 18
###xml 125 129 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Fonseca1">[15]</xref>
###xml 372 381 360 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g001">Figure 1A</xref>
###xml 665 674 653 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g001">Figure 1B</xref>
WFS1 expression is regulated by the master regulators of ER stress signaling, PERK and IRE1alpha, under ER stress conditions [15]. To determine whether PERK signaling is involved in WFS1 upregulation by valproate, we measured expression levels of phosphorylated eIF2alpha, which reflect PERK activation levels. Valproate did not increase eIF2alpha phosphorylation levels (Figure 1A upper panel), raising the possibility that WFS1 upregulation by valproate is not regulated by the ER stress signaling network. To test this idea, we measured mRNA expression levels of common ER stress response genes, GRP94, GRP78, total and spliced XBP-1, and AATF by real-time PCR. Figure 1B shows that expression levels of these ER stress markers did not change by valproate, indicating that valproate specifically upregulates WFS1 without activating other components of ER stress signaling.
###end p 18
###begin p 19
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi2">[22]</xref>
###xml 673 681 665 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g002">Figure 2</xref>
###xml 881 885 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi2">[22]</xref>
###xml 1316 1324 1308 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g002">Figure 2</xref>
It has been proposed that WFS1 mRNA expression is regulated by a 500-base-pair promoter region located upstream of its transcriptional start site [22]. We were therefore interested in determining whether this WFS1 promoter can be activated by valproate treatment. We transfected a neuronal cell line, SH-SY5Y cells, with a reporter plasmid containing 500 bases of the WFS1 promoter driving the luciferase gene or a control reporter plasmid containing only 60 bases of the WFS1 promoter, then treated these cells with two different concentrations of valproate. Valproate led to a seven fold (50 microg/ml) and a twelve fold (200 microg/ml) induction of luciferase activity (Figure 2, lanes 4 and 5). The same promoter could not be activated in non-neuronal 293T cells (data not shown). It has been postulated that XBP-1 is important in activating the WFS1 promoter in SH-SY5Y cells [22]. We therefore considered the possibility that the addition of valproate to XBP-1 expression can enhance luciferease activity. To test this idea, we co-transfected SH-SY5Y cells with XBP-1 expression plasmid along with the WFS1 reporter plasmid or the control plasmid with or without valproate treatment. As we predicted, the addition of valproate enhanced the induction of luciferase activity by XBP-1 in a dose-dependent manner (Figure 2, lanes 7 and 8). Collectively, these results indicate that valproate can strongly activate the WFS1 promoter together with XBP-1 specifically in neuronal cells.
###end p 19
###begin title 20
WFS1 promoter is activated by valproate.
###end title 20
###begin p 21
SH-SY5Y cells were transfected with a reporter plasmid containing 500 bases of the WFS1 promoter driving the luciferase gene (pGL3-WFS1-long), a control reporter plasmid containing only 60 bases of the WFS1 promoter (pGL3-WFS1-short), or control plasmid (pGL3) plus XBP-1 expression plasmid or control plasmid. The cells were then treated with two different concentrations of valproate, 50 microg/ml and 200 microg/ml, for 6 hr.
###end p 21
###begin title 22
Mood stabilizers modulate WFS1-GRP94 complex
###end title 22
###begin p 23
###xml 300 309 300 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3A</xref>
High-throughput proteomics analysis has shown that WFS1 interacts with GRP94 (Fonseca and Urano, manuscript in preparation). To confirm this, we examined the association of WFS1 with GRP94 in Neuro-2a cells by immunoprecipitation. As we predicted, WFS1 associated with GRP94 under normal conditions (Figure 3A, lane 2, upper panels, IP).
###end p 23
###begin title 24
Mood stabilizers modulate the WFS1-GRP94 complex.
###end title 24
###begin p 25
(A) Neuro-2a cells were treated with lithium (Li, 0.5 mM, 1 mM), valproate (VPA, 50 ug/ml, 100 ug/ml) for 48 hr or untreated. Wfs1 was immunoprecipitated (IP) using lysates from the cells with anti-Wfs1 antibody. IP products were immunoblotted (IB) with anti-GRP94 antibody or anti-Wfs1 antibody. (B) The ratio of the relative amount of immunoprecipitaed GRP94 to that of immunoprecipitated WFS1 is shown. The X axis indicates the concentration of each drug.
###end p 25
###begin p 26
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Bown1">[23]</xref>
###xml 464 473 464 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3A</xref>
###xml 599 608 599 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3A</xref>
###xml 644 653 644 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3B</xref>
It has been shown that valproate and lithium can modulate GRP94 expression in neurons [23], raising the possibility that this interaction can also be modulated with valproate and lithium. To test this possibility, we treated Neuro-2a cells with therapeutic concentrations of lithium or valproate for 48 hr, then examined the interaction between WFS1 and GRP94 by immunoprecipitation. The amount of GRP94 co-immunoprecipitated with WFS1 was decreased with lithium (Figure 3A, lanes 3 and 4, upper panels). The amount of WFS1 immnoprecipitated with anti-WFS1 antibody was also decreased with lithium (Figure 3A, lanes 3 and 4, lower panels, IP). Figure 3B shows that lithium treatment of Neuro-2a cells did not change the ratio between immunoprecipitated WFS1 and GRP94. These results suggest that lithium treatment may cause a conformational change of WFS1 protein, rendering the immunoprecipiation with anti-native-WFS1 antibody less efficient.
###end p 26
###begin p 27
###xml 71 80 71 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3A</xref>
###xml 190 199 190 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3A</xref>
###xml 334 343 334 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g003">Figure 3B</xref>
Valproate increased WFS1 expression levels in a dose-dependent manner (Figure 3A, lanes 5 and 6, lower panels, input). A parallel rise was observed in the amount of immunoprecipitated WFS1 (Figure 3A, lanes 5 and 6, lower panels, IP). Valproate decreased the ratio between immunoprecipiated WFS1 and GRP94 in a dose-dependent manner (Figure 3B), suggesting that WFS1 dissociates from GRP94 and that GRP94-free WFS1 is increased with valproate.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
Although it is well established that valproate is a standard treatment for bipolar disorder and a first-line mood stabilizer, its mechanism of action has not been fully elucidated. Our results demonstrate that valproate induces expression of WFS1 and enhances its dissociation from GRP94 in neurons. We propose that the therapeutic effect of valproate is partially mediated by modulation of ER stress through the regulation of WFS1 and GRP94.
###end p 29
###begin p 30
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi2">[22]</xref>
###xml 467 475 467 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g002">Figure 2</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi2">[22]</xref>
Valproate strongly activates the promoter region of WFS1 gene. We have previously shown that the minimum element for WFS1 promoter activation under ER stress conditions. The sequence of the element was similar to the one of ER stress response element (ERSE). We called it ERSE-like element [22]. The upregulation of WFS1 by valproate is probably regulated by the same element because the promoter lacking this sequence, pGL3-WFS1-short, did not respond to valproate (Figure 2). Consistent with previous results, this activation can be enhanced by co-transfection of the transcription factor XBP-1. It is possible that this activation might be indirect because our previous result indicated that XBP-1 could not directly bind to the ERSE-like element [22]. Other unknown transcription factors induced by XBP-1 or interacted with XBP-1 may have a function in the activation of WFS1 promoter.
###end p 30
###begin p 31
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi1">[14]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Kakiuchi1">[14]</xref>
###xml 945 953 945 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004134-g004">Figure 4</xref>
High-throughput proteomics analysis revealed that GRP94 was one of the proteins that could interact with WFS1 in 293T cells (Fonseca and Urano, manuscript in preparation). Our data indicate that valproate enhances dissociation of WFS1 from GRP94. Considered collectively, valproate may regulate the UPR by modulating the interaction between GRP94 and WFS1. Genetic variations in the GRP94 gene are strongly associated with bipolar disorder in the Japanese population [14]. The protective GRP94 allele associated with bipolar disorder was related to low mRNA expression of GRP94 [14]. Downregulation of GRP94 may increase the amount of GRP94-free WFS1, leading to the enhancement of WFS1 function. Thus, the downregulation of GRP94 may have the same effect as the upregulation of WFS1. It is also possible that upregulation of WFS1 by valproate increases the ratio between GRP94-free WFS1 and GRP94-bound WFS1, leading to the activation of WFS1 (Figure 4).
###end p 31
###begin title 32
A speculative model of the action of valproate in the regulating of WFS1 and in the treatment of bipolar disorder.
###end title 32
###begin p 33
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004134-Lawson1">[24]</xref>
GRP94 is an ER resident member of the HSP90 family of molecular chaperones. It has been shown that an HSP90 inhibitor, geldanamycin, can bind to GRP94, inhibit its function, and increase the transcription of ER molecular chaperones [24]. It would be possible that geldanamycin as well as its less toxic analogues, 17-AAG and GA, may synergize with valproate and increase its effect on WFS1 expression and modulation of the WFS1-GRP94 complex. Thus, inhibitors of GRP94 function could be a novel class of drug for bipolar disorder.
###end p 33
###begin p 34
###xml 347 355 <span type="species:ncbi:9606">patients</span>
In this study, we focused on the function of valproate in WFS1 expression and its interaction with GRP94. The modulation of ER stress through the activation of WFS1 may be part of valproate's action in bipolar disorder. Our findings suggest that valproate and a compound that can reduce GRP94 expression in neurons may be a valuable treatment for patients with bipolar disorder.
###end p 34
###begin title 35
Methods
###end title 35
###begin title 36
Cell culture
###end title 36
###begin p 37
###xml 79 85 <span type="species:ncbi:9913">bovine</span>
Neuro-2a cells, SH-SY5Y, and 293T cells were maintained in DMEM with 10% fetal bovine serum.
###end p 37
###begin title 38
Immunoblotting and immunoprecipitation
###end title 38
###begin p 39
Cell extracts were prepared by lysis in TNE buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA and 0.1% NP40) containing protease inhibitors and phosphatase inhibitor Cocktail 2 (SIGMA) for 15 min on ice, then the extracts were cleared by centrifuging at 12,000 g for 20 min at 4degreesC. Extracts were normalized for total protein (10 microg per lane), separated using 4%-20% linear gradient SDS-PAGE (Bio Rad, Hercules, CA) and electroblotted. Blots were probed with the following antibodies: anti-actin (Sigma, St. Louis, MO); anti-phospho-eIF2alpha, anti-GRP94 (Cell Signaling, Danvers, MA). The amount of protein was quantified using ImageJ software. For the immunoprecipitation, cells extracts were prepared by lysis in TNE buffer containing protease inhibitors for 15 min on ice. WFS1 was immunoprecipitated from the extracts with anti-WFS1 antibody, a gift from Drs. Hisamitsu Ishihara and Yoshitomo Oka (Tohoku University, Japan).
###end p 39
###begin title 40
Luciferase Assay
###end title 40
###begin p 41
SH-SY5Y cells were transfected with a reporter plasmid containing 500 bases of the WFS1 promoter driving the luciferase gene (pGL3-WFS1-long), a control reporter plasmid containing only 60 bases of the WFS1 promoter (pGL3-WFS1-short), or control plasmid (pGL3) plus XBP-1 expression plasmid or control plasmid using Lipofectaminetrade mark 2000 (Invitrogen, Carlsbad, CA). 48 hrs post-transfection, the cells were treated with two different concentrations of valproate, 50 microg/ml and 200 microg/ml, for 6 hr and then lysed using a Luciferase Assay System kit (Promega, Madison, WI). The light produced from the samples was read by a plate reading luminometer, Victor X (Perkin Elmer, Waltham, MA). Each sample was read in triplicate and normalized against the signal produced from mock wells.
###end p 41
###begin title 42
Real-time polymerase chain reaction
###end title 42
###begin p 43
###xml 791 811 769 789 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCAAGTGCTTCTAGGCGGAC</named-content>
###xml 816 838 794 816 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AAGAAAGGGTGTAAAACGCAGC</named-content>
###xml 856 876 834 854 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CCATCAACATGCTCCCGTTC</named-content>
###xml 881 900 859 878 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GGGTAGGCCTCGCCATACA</named-content>
###xml 919 945 897 923 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AAGAATGAAGGAAAAACAGGACAAAA</named-content>
###xml 950 970 928 948 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAAATGGAGAAGATTCCGCC</named-content>
###xml 989 1013 967 991 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTCAGCCAATTATCAGCAAACTCT</named-content>
###xml 1018 1044 996 1022 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTTTCTGATGTATCCTCTTCACCAGT</named-content>
###xml 1069 1090 1047 1068 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TGGCCGGGTCTGCTGAGTCCG</named-content>
###xml 1095 1116 1073 1094 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTCCATGGGAAGATGTTCTGG</named-content>
###xml 1143 1164 1121 1142 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CTGAGTCCGAATCAGGTGCAG</named-content>
###xml 1169 1189 1147 1167 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GTCCATGGGAAATGTTCTGG</named-content>
###xml 1201 1225 1179 1203 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AATF, TTCTTGGCAAACCGGAGC</named-content>
###xml 1230 1250 1208 1228 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGCGTCTCTGGTTCTCCTGG</named-content>
###xml 778 783 <span type="species:ncbi:10090">mouse</span>
###xml 844 849 <span type="species:ncbi:10090">mouse</span>
###xml 906 911 <span type="species:ncbi:10090">mouse</span>
###xml 976 981 <span type="species:ncbi:10090">mouse</span>
###xml 1050 1055 <span type="species:ncbi:10090">mouse</span>
###xml 1122 1127 <span type="species:ncbi:10090">mouse</span>
###xml 1195 1200 <span type="species:ncbi:10090">mouse</span>
Total RNA was isolated from the cells with the RNeasy Mini Kit (Qiagen, Valencia, CA) and reverse transcribed using 1 microg of total RNA from cells with Oligo-dT primer. For the thermal cycle reaction, the iQ5 system (BioRad, Hercules, CA) was used at 95degreesC for 10 min, then 40 cycles at 95degreesC for 10 sec, and at 55degreesC for 30 sec. The relative amount for each transcript was calculated by a standard curve of cycle thresholds for serial dilutions of cDNA sample and normalized to the amount of actin. The polymerase chain reaction (PCR) was done in triplicate for each sample, then all experiments were repeated three times. The following sets of primers and Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) were used for real-time PCR: for mouse actin, GCAAGTGCTTCTAGGCGGAC and AAGAAAGGGTGTAAAACGCAGC; for mouse WFS1, CCATCAACATGCTCCCGTTC and GGGTAGGCCTCGCCATACA; for mouse GRP94, AAGAATGAAGGAAAAACAGGACAAAA and CAAATGGAGAAGATTCCGCC; for mouse GRP78, TTCAGCCAATTATCAGCAAACTCT and TTTTCTGATGTATCCTCTTCACCAGT; for mouse total XBP-1, TGGCCGGGTCTGCTGAGTCCG and GTCCATGGGAAGATGTTCTGG; for mouse spliced XBP-1, CTGAGTCCGAATCAGGTGCAG and GTCCATGGGAAATGTTCTGG; for mouse AATF, TTCTTGGCAAACCGGAGC and AGCGTCTCTGGTTCTCCTGG.
###end p 43
###begin p 44
We thank Jeannette Osterloh, Kavitha Padmanabhan, and members of the Urano lab for discussions and critical reading of the manuscript.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
Manic-depressive illness.
###end article-title 46
###begin article-title 47
Molecular genetics of bipolar disorder and depression.
###end article-title 47
###begin article-title 48
The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?
###end article-title 48
###begin article-title 49
Mechanisms of action of valproate: a commentatory.
###end article-title 49
###begin article-title 50
Valproate: past, present, and future.
###end article-title 50
###begin article-title 51
Increase in AP-1 transcription factor DNA binding activity by valproic acid.
###end article-title 51
###begin article-title 52
Valproate robustly enhances AP-1 mediated gene expression.
###end article-title 52
###begin article-title 53
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
###end article-title 53
###begin article-title 54
Signal integration in the endoplasmic reticulum unfolded protein response.
###end article-title 54
###begin article-title 55
That which does not kill me makes me stronger: adapting to chronic ER stress.
###end article-title 55
###begin article-title 56
The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins.
###end article-title 56
###begin article-title 57
Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors.
###end article-title 57
###begin article-title 58
OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD.
###end article-title 58
###begin article-title 59
Association analysis of HSP90B1 with bipolar disorder.
###end article-title 59
###begin article-title 60
WFS1 Is a Novel Component of the Unfolded Protein Response and Maintains Homeostasis of the Endoplasmic Reticulum in Pancreatic {beta}-Cells.
###end article-title 60
###begin article-title 61
###xml 54 62 <span type="species:ncbi:9606">patients</span>
A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).
###end article-title 61
###begin article-title 62
Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein.
###end article-title 62
###begin article-title 63
Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1.
###end article-title 63
###begin article-title 64
Psychiatric findings in Wolfram syndrome homozygotes.
###end article-title 64
###begin article-title 65
Predisposition of Wolfram syndrome heterozygotes to psychiatric illness.
###end article-title 65
###begin article-title 66
Wolframin mutations and hospitalization for psychiatric illness.
###end article-title 66
###begin article-title 67
XBP1 induces WFS1 through an endoplasmic reticulum stress response element-like motif in SH-SY5Y cells.
###end article-title 67
###begin article-title 68
###xml 103 106 <span type="species:ncbi:10116">rat</span>
Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells.
###end article-title 68
###begin article-title 69
Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
###end article-title 69
###begin p 70
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 70
###begin p 71
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Research in the laboratory of F. Urano is supported by an NIH R01DK067493 grant, a grant from the Diabetes and Endocrinology Research Center at the University of Massachusetts Medical School, a Juvenile Diabetes Research Foundation Regular Research Grant, an Iacocca Foundation Grant, and an Worcester Foundation for Biomedical Research Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 71

